logo
I paid £15,000 for arranging IVF – then the service went bust

I paid £15,000 for arranging IVF – then the service went bust

Yahoo5 hours ago

IVF patients are being warned over unregulated "concierge clinics" after a popular one went bust leaving scores of clients without treatment or refunds.
As the number of privately funded IVF cycles has risen, online concierge companies have emerged, acting as "middlemen" between patients, donors and doctors.
The fertility watchdog has said that as these clinics do not provide IVF treatment directly, it does not have powers to regulate them. It is calling for the law to be strengthened to protect patients.
Syreeta Sandhu lost nearly £15,000 when her concierge clinic went bust. "You're on your knees," she said. "Upset has turned to frustration and anger."
The 40-year-old mother-of-two contacted online firm Apricity Fertility after four failed rounds of IVF and five miscarriages, in the hope of having a third child.
She paid Apricity, which matched her with an egg donor and contracted established clinic King's Fertility. She was due to start treatment in December last year when her appointments were cancelled without explanation.
Syreeta found out via the company's app that it was ceasing operations on 1 January.
When she contacted King's, the clinic said data protection rules meant it did not have access to her file or details of her egg donor. It had not been paid by Apricity so her treatment could not begin.
"When you're on this journey, every month counts. You'll do anything, and you do throw lots of money at it," she said.
"It takes a long time to meet [medical staff] you can trust," she said. "I spent almost 12 months building that trust and it just dropped off."
Concierge clinics offer services like matching patients with donors and doctors, booking appointments and posting medication.
It is not clear how many there are operating in the UK but experts believe their number is growing.
Satellite arrangements – where patients attend medical appointments with one doctor, usually their own GP, and then undergo the IVF process elsewhere – is an established set-up in fertility care. But concierge clinics don't have physical premises or store eggs, sperm or embryos themselves.
The fertility watchdog, the Human Fertilisation and Embryology Authority (HFEA), is warning patients that these new services are not covered by its protections.
Clare Ettinghausen, director of strategy and corporate affairs at the HFEA, said: "The fallout from Apricity's closure and the effect it had on patients highlights how the current law does not reflect the range and type of fertility treatments being offered today."
She said the watchdog was calling for the Human Fertilisation and Embryology Act to be revised to take account of the different ways fertility services are provided.
Syreeta is one of 52 patients owed money by Apricity. The company owes a total of £119,000 to its patients, according to the liquidator appointed to manage its debts, Cork Gully.
Beth Rodgers, 32, from Belfast has Turner syndrome, a rare genetic condition that means her ovaries do not produce eggs. Because Northern Ireland has a severe shortage of donor eggs, Beth had to secure a donor in England.
She and her partner paid Apricity £4,600 and had been matched with an egg donor.
"Then I saw a comment on a Facebook group saying 'thinking of everyone affected by the Apricity news,'" she said. "There was no communication, no number to call."
The couple were able to claim some of the money back on their insurance but it did not cover a £385 fee for a doctor's appointment and £985 for donor compensation.
"Time was probably the biggest thing I felt I lost. It was such a long process," said Beth.
She has now restarted treatment with a regulated clinic. She has had appointments with a doctor in the Republic of Ireland and travelled to Manchester for the embryo transfer.
That transfer was unsuccessful but she will be able to get another round of IVF on her insurance with a different egg donor.
In recent years, more British couples have paid for private fertility treatment, in part because IVF on the NHS is a postcode lottery.
Jonathan, not his real name, and his wife went through five failed rounds of IVF before they went to Apricity. They paid £10,000 for treatment with their savings and a loan.
"We've been told there's no realistic chance of getting our money back," he said. "We haven't been able to resume treatment yet as we're still trying to raise finance."
Cork Gully told Jonathan and other patients in a letter seen by the BBC: "It is unlikely that there will be funds to pay to patients."
It said any affected patients should get in touch.
The BBC asked Mel Chacksfield, who was chief executive of Apricity when it ceased operations, why the business had gone under and if patients would be refunded but she did not respond to our request.
However, Caroline Noublanche, one of the company's founders and the previous chief executive, told the BBC it had "faced sudden and irreversible financial difficulties in December when planned investment from an investor was withdrawn".
Prof Emily Jackson is a researcher in medical law and ethics at the London School of Economics. She said: "You need a licence to do things with embryos and sperm and eggs but you don't need any licence to offer to arrange things on the internet.
"For people thinking about their options, it is probably sensible to opt for treatment in an HFEA-licensed clinic, because they have responsibilities towards patients in the event of closure."
Those responsibilities mean that if an HFEA-licensed clinic closes, it has to give patients information and ensure they are supported.
The clinic must also ensure all eggs, sperm and embryos that are in storage are kept safe.
A spokesperson for the Department of Health and Social Care told BBC News: "While digital or 'virtual' clinics do not currently fall within the remit of the Human Fertilisation and Embryology Authority, ministers have met with its chair to discuss the emerging regulatory challenges.
"The government is currently considering the HFEA's recommendations on modernising fertility law. We would advise all those looking at using digital clinics to carry out thorough research before making any decisions."
King's Fertility, which was providing Syreeta's treatment, was a contractor of Apricity's and is now a creditor of the company.
Its director, Dr Ippokratis Sarris, a consultant in reproductive medicine, said it was likely more concierge clinics would emerge in the future as patients look for convenience and flexibility.
"The shift toward more remote and digital models of care is an inevitable progression in today's world. This is increasingly what patients want, and often prefer, so it's important that we don't deny them that choice."
But he advised patients to do careful research before choosing a provider, and to be cautious about paying upfront for multi-cycle packages.
"It's wise to look into how long a clinic has been established, who owns it (NHS, private individual, or private equity), and make an informed choice," he added.
"We shouldn't resist change, but we do need to be proactive in shaping it responsibly."
More single women and female couples having IVF
Fertility patients sold unproven add-ons, HFEA says
Couple shocked at free IVF rejection by NHS

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

World's most deadly viruses to be held at new lab in Surrey
World's most deadly viruses to be held at new lab in Surrey

Yahoo

timean hour ago

  • Yahoo

World's most deadly viruses to be held at new lab in Surrey

Cutting-edge laboratories to hold and study the world's most deadly diseases are to be built in Surrey. Fatal and incurable viruses will be researched at a new facility in Weybridge to help prevent future pandemics and also to prepare for a potential terror attack with a biological weapon. The new National Biosecurity Centre will have the highest classification of lab biosecurity to analyse the most dangerous diseases, known as biosafety level four pathogens, which include Ebola. This upgrade in biosecurity at Weybridge puts it on equivalent footing to the UK Healthy Security Agency (UKHSA) base at Porton Down, but on a much bigger scale, as it will test and study infected farm animals, not just rodents. The Department for Environment, Food and Rural Affairs (Defra) on Monday announced £1 billion of taxpayer money to fund the centre, as part of a £2.8 billion overhaul of the Government's marquee animal disease site. The level four labs will allow staff to safely handle deadly diseases by working in self-contained suits with a dedicated air supply, air locks upon entry and exit, negative air pressure, airtight facilities, and chemical disinfection showers. Scientists will use the new facilities, due to open in 2033, to prevent outbreaks of disease. This includes known pathogens, but also as yet unknown future outbreaks such as 'Disease X', a hypothetical pathogen that will cause the next pandemic, officials say. Environment Secretary Steve Reed told The Telegraph: 'Covid happened once and it can happen again, so we need to invest in the world-class facilities we need to keep not just the economy safe, but the people in this country safe. 'This will be one of only five or six facilities in the world up to this standard. Somebody described this national biosecurity centre to me as being the MI5 of animal and plant disease.' It will also allow the centre to lead on anti-bioterrorism work to ensure that diseases of plants or animals are not weaponised against Britain. The National Biosecurity Centre will work alongside scientists at the MoD's Defence Science and Technology Laboratory and the UKHSA facilities at Porton Down. This three-pronged network will form the backbone of the tranche of the UK's National Security Strategy against biological agents, both zoonotic and from hostile states. Around 60 per cent of all diseases are zoonotic and spread to humans via animals. Mr Reed said: 'In the same way pathogens can be used against humans, they can be used against the plants and animals we depend on for food. 'This site will be part of a network of facilities we need to strengthen national security. This is where bioweapon work will be researched and tackled so that we can recognise it, should it happen, and then have the means to combat it.' The Weybridge site is the main research centre of the Animal and Plant Health Agency (APHA) and has been criticised for being in poor condition. Scientists at these labs lead the response to bird flu, foot-and-mouth disease, and bluetongue. It is also where swabs from the recent rabies fatality were tested. Mr Reed added: 'The money is so desperately needed. You can see just from looking around that these are very old facilities – some remind me of my old science lab at school. 'It shouldn't look like that, it should be a world-class facility. It has world-class people working in it, but the buildings and the tools are not up to the standard they need to be. The previous Government let them become close to obsolete. 'This investment is desperately needed now to protect food production, farming and the economy as well as human beings.' A 2022 National Audit Office report found the site to be in shoddy shape, with it having the highest possible risk of failure possible, and warned it would be unable to cope with a serious outbreak. Dr Jenny Stewart, APHA Senior Science Director, told The Telegraph: 'The new centre will add some new capabilities that will let us deal with diseases that we can't currently deal with on this site, and allow us to do research. 'That will mean that we're ready for the next thing that comes. We have a thing called 'Pathogen X', or 'Disease X', and at this site we can be ready for whatever that might be. 'The step change is that we're going to have a higher level of containment on the site that lets us deal with more dangerous diseases than we currently manage on this site. 'We keep saying we are a Reliant Robin, and we are getting a spacecraft.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

ThinkSono Secures Additional £4.5M / $6Mn Funding, Expands Team and Operations Across the UK, EU and U.S.
ThinkSono Secures Additional £4.5M / $6Mn Funding, Expands Team and Operations Across the UK, EU and U.S.

Associated Press

time2 hours ago

  • Associated Press

ThinkSono Secures Additional £4.5M / $6Mn Funding, Expands Team and Operations Across the UK, EU and U.S.

LONDON, GB / ACCESS Newswire / June 25, 2025 / ThinkSono, a pioneering ultrasound AI company, has built the world's first software for DVT (blood clot) detection. For context, DVT is a leading cause of morbidity and mortality worldwide, and up to 900,000 people in the U.S are affected by DVT each year [1]. The company has successfully completed its second oversubscribed seed funding round, securing an additional £4.5Mn ($6Mn / €5.4Mn). It has raised £9.6Mn ($13Mn / €11.3Mn) to date. The latest round is led by id4 ventures, and joined by Brandenburg Kapital, Cur8 Capital and several key opinion leaders (KOLs) in vascular surgery. The company founders also participated in the funding round in alignment with other investors. Momentum & Milestones: This significant investment builds upon the regulatory, clinical, and commercial momentum the company has already achieved since raising £2.1Mn ($2.8Mn / €2.5Mn) in 2024. It obtained the world's first Class IIb CE mark for AI software to detect DVT. The new funding has enabled the company to increase its team size and fill key positions, including a CFO, Sales Director, Chief Compliance Officer, UK Medical Director, and expand its medical advisory board. In addition, the company has expanded its U.S. operations with key staff and is progressing with multi-centred clinical trials for subsequent FDA filing for its ThinkSono Guidance software. Prominent U.S. Hospitals, including NYU Langone Health, Allegheny Health Network (AHN), Temple Health, and UW Health University Hospital, have been selected as key sites. Finally, the company has published a peer-reviewed paper in npj Digital Medicine that shows excellent clinical and health economic results. Due to its importance, this study has also been highlighted in npj Digital Medicine as an Editorial. This achievement underscores the company's commitment to delivering cutting-edge AI solutions that meet rigorous quality and safety standards, positioning ThinkSono as a leader in the field of AI ultrasound guidance. ThinkSono has partnered with hospitals across the U.S. and Europe, including the UK, Germany, Greece and Poland. Comments from CEO and KOLs: Fouad Al Noor, CEO and Co-founder of ThinkSono: 'This funding shows that leading investors are doubling down on ThinkSono, and our confidence is further reinforced by having clinical KOLs investing alongside our investors. We're also very pleased to have an extremely competent team that will be supporting our UK/EU commercialisation efforts as well as our U.S. FDA clearance process' Michael Blaivas, Professor of Emergency Medicine, and ThinkSono's Chief Medical Officer: 'The inability to quickly and timely rule out lower extremity DVT has been the bane of healthcare providers for decades. This problem impacts settings from office practices, clinics, emergency departments, hospital floors to intensive care units and more. ThinkSono's technology addresses this problem directly and has the potential to significantly improve patient care across Europe and beyond.' Glenn Jacobowitz, ThinkSono Clinical Advisor, Professor of Vascular Surgery and the Director of Ambulatory Vascular Surgery, Western Region at Northwell Health: 'The ThinkSono Guidance System would be a powerful tool in our diagnostic arsenal. It's the kind of innovation that can literally change the way high-quality, efficient care is delivered to patients on a daily basis. The potential impact in the US and abroad is enormous.' Dr Satish Muluk, director of vascular surgery at Allegheny Health Network: 'This breakthrough technology has the potential to dramatically improve patient outcomes by accelerating DVT detection and subsequent care. By empowering a wider range of healthcare professionals to perform this imaging procedure, we can reach patients more quickly and minimize delays in lifesaving treatment.' 'The fact that ThinkSono's technology can be used by a variety of healthcare staff, instead of only sonogram-trained technicians, is a significant benefit amid the ongoing healthcare workforce shortage, which includes ultrasound technicians and qualified sonographers' [2] About ThinkSono: ThinkSono is a leading ultrasound AI technology company specialising in ultrasound guidance solutions. Its software has been peer reviewed in multiple studies across more than 10 hospitals and with more than 1,000 patients scanned in trials across the UK, Germany, Greece and the U.S. Its technology is clinically validated with strong peer-reviewed health economics. Contact: [email protected] Regulatory information The EU (MDR) Class IIb Intended Purpose of ThinkSono Guidance is found here: Research: All published research found here: References: [1] [2] AHN Press release: Note: ThinkSono Guidance is not FDA cleared and will not be available in the U.S. until full clearance is given. Please contact [email protected] for more information. Approximate conversion from GBP to USD and EUR based on 24 Jun, 15:22 UTC from Morningstar Contact Information Fouad Noor CEO [email protected] SOURCE: ThinkSono Ltd press release

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Yahoo

time2 hours ago

  • Yahoo

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC ('Kashiv'), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited ('Advanz Pharma'), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic. The randomized, double-blind, multicenter study assessed the efficacy, safety, and immunogenicity of AVT23 compared to Xolair® in patients with Chronic Spontaneous Urticaria (CSU), who remained symptomatic despite treatment with H1 antihistamines. The study met its primary endpoint, with data demonstrating equivalence of therapeutic endpoints and comparable safety between the biosimilar candidate and the reference biologic. Participants received subcutaneous doses of either 150 mg or 300 mg every four weeks over a 24-week period. A total of 600 patients were enrolled, and efficacy and safety were evaluated in 400 patients who received the confirmatory dose of 300 mg. The primary efficacy measure was the change from baseline in the weekly Itch Severity Score (ISS7) at Week 12 between the treatment groups of ADL-018 and reference product. 'The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase global patient access to this important medicine,' said Joseph McClellan, Chief Scientific Officer of Alvotech. 'This marks a positive advancement for Kashiv's growing biosimilar pipeline in addition to its current portfolio of Releuko® and Fylnetra®. We look forward to collaborating with regulatory authorities to make this treatment available to patients,' said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv BioSciences, 'We remain focused on delivering cost-effective, high-quality therapies to improve patient outcomes globally, working with commercial partners such as Alvotech and Advanz Pharma.' 'The successful confirmatory efficacy results for the proposed biosimilar to XOLAIR® mark an important milestone in Advanz Pharma's ambition to expand patient access to specialty medicines across our core geographies, Europe, Canada, and Australia.' said Nick Warwick, Chief Medical Officer at Advanz Pharma. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has already validated and accepted the marketing authorization application (MAA) for AVT23 earlier this year, and the filing of an MAA with the European Medicines Agency (EMA) is expected before the end of the year. About AVT23AVT23 is a proposed biosimilar to Xolair® (omalizumab). Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E (IgE). Xolair®, which contains omalizumab, is indicated for severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy [1]. AVT23 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. Alvotech partnered with Kashiv BioSciences for the development of the proposed Xolair® biosimilar, which is referred to as AVT23 by Alvotech and as ADL-018 by Kashiv Biosciences. Use of trademarksXolair® is a registered trademark of Novartis AG. Sources[1] MHRA Product Information for Xolair® About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability get marketing approval for AVT23 in the UK and other jurisdictions; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. About Advanz PharmaPartner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Advanz Pharma Forward Looking StatementsCertain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', "expectation", "belief', "estimate", "plan", "target', 'project', 'will', 'may', 'should' or "forecast" and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. About Kashiv BioSciences:Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together 'Kashiv BioSciences') operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. CONTACTS Alvotech Investor Relations and Global CommunicationsBenedikt Stefansson, Advanz Pharma Global Corporate CommunicationsCourtney Kashiv BiosciencesDr. Paras

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store